<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931928</url>
  </required_header>
  <id_info>
    <org_study_id>IKP275 / GBG91</org_study_id>
    <secondary_id>2016-000418-31</secondary_id>
    <nct_id>NCT03931928</nct_id>
  </id_info>
  <brief_title>Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients</brief_title>
  <acronym>TAMENDOX</acronym>
  <official_title>Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients (TAMENDOX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Bosch Gesellschaft für Medizinische Forschung mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Robert Bosch Gesellschaft für Medizinische Forschung mbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen
      remains an important treatment option for patients before menopause and those patients after
      menopause who cannot be treated with aromatase-inhibitors. Nonetheless, a considerable amount
      of patients suffer a relapse of their cancer while on treatment with tamoxifen. Tamoxifen is
      a drug that is metabolized to a variety of compounds by the human liver, and the most
      important antihormonally active metabolite is called (Z)-Endoxifen. It is known that patients
      who have a reduced or absent activity of the drug-metabolizing enzyme CYP2D6 have lower
      levels of (Z)-Endoxifen. Furthermore, it has been observed that patients on tamoxifen therapy
      who have absent CYP2D6 activity are at a 2-fold increased risk for disease recurrence, and
      patients with lower CYP2D6 compared to patients with normal CYP2D6 activity still have a
      1.4-fold increased risk for disease recurrence.

      This trial will include patients who are already on tamoxifen therapy for at least 3 months
      and is designed to show that in patients with absent or low CYP2D6 activity, (Z)-Endoxifen
      supplementation - that is giving (Z)-Endoxifen in addition to tamoxifen for the study period
      of 42 days - can increase blood levels of (Z)-Endoxifen to therapeutic concentrations. It is
      planned to included 504 patients in this blinded, randomized trial, which will have a placebo
      group (receiving no (Z)-Endoxifen) and two intervention groups that will receive 0, 1.5 or 3
      mg (Z)-Endoxifen depending on their CYP2D6 genetics or their (Z)-Endoxifen levels at the
      start of the study.

      The trial is not designed to evaluate outcome measures (that is recurrence or survival rates)
      of (Z)-Endoxifen supplementation in tamoxifen treated patients, but will document the safety
      of the combined administration of tamoxifen and (Z)-Endoxifen.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    COVID-19 pandemic
  </why_stopped>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Z-)endoxifen plasma concentration &gt; 32 nM</measure>
    <time_frame>42 days (-2 days/+7 days)</time_frame>
    <description>The primary endpoint is reached if in one or both intervention groups, the proportion of patients with steady state (Z)-endoxifen plasma concentration &gt; 32 nM is greater or equal to the proportion of patients in the control group that reaches steady state (Z)-endoxifen plasma concentration of &gt; 32 nM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in steady state (Z)-endoxifen concentration</measure>
    <time_frame>42 days (-2 days/+7 days)</time_frame>
    <description>Increase in steady state (Z)-endoxifen concentration from baseline to end of intervention (Visit 3) in patients with or without supplementation of (Z)-endoxifen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in steady state plasma concentrations of tamoxifen, desmethyltamoxifen, 4-hydroxytamoxifen and other tamoxifen metabolites following (Z-)endoxifen supplementation</measure>
    <time_frame>42 days (-2 days/+7 days)</time_frame>
    <description>Assessment of steady state plasma concentrations of tamoxifen, desmethyltamoxifen, 4-hydroxytamoxifen, and other tamoxifen metabolites following (Z)-endoxifen supplementation for 6 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])</measure>
    <time_frame>AE/SAE occurring while the subject is on IMP, or within 28 days of the patient's last dose of IMP</time_frame>
    <description>All AE/SAE occuring in the intervention period will descriptively reported</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Breast Cancer</condition>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>Control group (Group 1)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients receive Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (Z)-endoxifen dosed according to CYP2D6 &quot;genotype&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Z)-Endoxifen supplementation according to genotype</intervention_name>
    <description>Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Z)-Endoxifen supplementation according to plasma levels</intervention_name>
    <description>Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, &gt; 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and &gt; 25 nM receive 0 mg (Placebo)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained prior to study entry. The patient must be accessible
             for scheduled visits and treatment.

          2. Pre- and postmenopausal women with ductal carcinoma in situ (DCIS) or early stage
             breast cancer. This includes stage I, IIA, IIB, and IIIA breast cancers.

          3. ER+/PR+, ER+/PR- or ER-/PR+ receptor status. Criteria for endocrine sensitivity is ≥1%
             ER-positive or PR-positive tumor cells on immune-histochemical staining

          4. Patients on standard tamoxifen monotherapy (20 mg/d) for at least three months or
             patients who had switched from AI to tamoxifen who are on tamoxifen treatment for at
             least three months

          5. Age ≥ 18 years

          6. Body mass index of 18.5 to 30.0 kg/m2

          7. The Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          8. Absolute neutrophil count greater than or equal to 1 500/µL

          9. Platelets greater than or equal to 100 000/µL

         10. Total bilirubin within less than or equal to 1.5 times institutional upper limit of
             normal

         11. AST/ALT less than or equal to 2.5 times institutional upper limit of normal

         12. The subjects need to be either

               1. of non-childbearing potential (documented postmenopausal status, defined as no
                  menses for 12 months without an alternative medical cause, or post hysterectomy,
                  bilateral salpingectomy or bilateral oophorectomy) or

               2. of childbearing potential (WOCBP) with negative serum pregnancy test (due to the
                  known reproduction toxicity of tamoxifen found in preclinical studies, WOCBP need
                  to use a highly effective non-hormonal contraception. These are copper IUDs,
                  bilateral tubal ligation, a vasectomized partner (vasectomy at least three months
                  prior to screening) or sexual abstinence. Male or female condoms with/ without
                  spermicide or caps, diaphragms or sponges with spermicide are associated with a
                  failure rate &gt; 1% per year and are thus not sufficient during the intervention
                  period.

         13. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical
             procedures to NCI CTCAE version 5.0 Grade ≤ 2 (except alopecia or other toxicities not
             considered a safety risk for the patient at investigator's discretion)

         14. Surgery and radiation therapy of the breast has to be completed upon study entry

        Exclusion Criteria:

          1. Subjects who are unable to understand written and verbal instructions

          2. Locally advanced (Stadium IIIB or IIIC) or metastatic (Stage IV) breast cancer

          3. Ongoing chemotherapy and/or treatment with trastuzumab within the last three months;
             participation in another trial with any investigational/not-marketed drug within 3
             months prior to baseline visit

          4. Other active second malignancy

          5. Invalid result of genotyping

          6. Pregnancy

          7. Breast feeding/lactation

          8. Oral contraceptives containing estrogens and/or progesterones

          9. Pathologic vaginal bleeding in pre-menopausal women or vaginal bleeding in
             post-menopausal patients

         10. Current severe acute somatic or psychiatric condition or laboratory abnormality that
             may increase the risk associated with study participation or may interfere with the
             interpretation of study results and, in judgement of the investigator, would make the
             patient inappropriate for entry into this study.

         11. Severe chronic cardiac or pulmonary disease (heart failure NYHA class 3 and 4), COPD
             GOLD C or D

         12. Chronic or acute renal disease with a glomerular filtration rate &lt; 60 ml/min/1.73 m2,
             and any patient on peritoneal dialysis or hemodialysis

         13. Medical history of thromboembolism (deep vein thrombosis or pulmonary embolism)

         14. QTc interval &gt;0.45 sec at screening ECG

         15. Concurrent treatment with strong to moderate inhibitors of CYP2D6 which may alter
             tamoxifen metabolism (Consortium on Breast Cancer Pharmacogenomics 2008):

             paroxetine, fluoxetine, bupropion, quinidine and duloxetine, diphenhydramine,
             thioridazine, amiodarone, cimetidine, sertraline

         16. Known allergies against an ingredient of the investigational product or tamoxifen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients with ductal carcinoma in situ (DCIS) or early stage breast cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Schwab, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Margarete Fischer-Bosch-Institute of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg und Medizinisches Versorgungszentrum am Bruderwald (MVZ)</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Köpenick, Brustzentrum</name>
      <address>
        <city>Berlin Köpenick</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Bottrop gGmbH, Klinik f. Gynäkologie u. Geburtshilfe</name>
      <address>
        <city>Bottrop</city>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Diakonie-Krankenhaus gGmbH, Frauenklinik</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luisenkrankenhaus Düsseldorf GmbH &amp; Co. KG, Brustzentrum</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40235</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Eggenfelden, Frauenärzte am Schellenbruckplatz</name>
      <address>
        <city>Eggenfelden</city>
        <zip>84307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen GmbH, Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH, Klinik für Frauenheilkunde/Geburtsmedizin</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Gifhorn, Interdisziplinäres Brustzentrum</name>
      <address>
        <city>Gifhorn</city>
        <zip>38518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ am Schlosssee GmbH</name>
      <address>
        <city>Gifhorn</city>
        <zip>38518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Gynäkologie</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe, Frauenklinik</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViDiA Christliche Kliniken Karlsruhe, Vincentius-Diakonissen Kliniken gAG, Diakonissenkrankenhaus</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus Kassel gGmbH, Brustzentrum</name>
      <address>
        <city>Kassel</city>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Krefeld, Zentrum für ambulante gyn. Onkologie (ZAGO)</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln GmbH, Krankenhaus Holweide</name>
      <address>
        <city>Köln</city>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg, Klinik für Frauenheilkunde und Geburtshilfe, Ambulantes Tumorzentrum</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg gGmbH, Klinik f. Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Memmingen</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>medius Kliniken gGmbH, medius Klinik Nürtingen, Brustzentrum</name>
      <address>
        <city>Nürtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>medius Kliniken gGmbH, medius Klinik Ostfildern-Ruit, Brustzentrum</name>
      <address>
        <city>Ostfildern</city>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau, Frauenklinik</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Quedlinburg Frauenklinik</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg, Frauenklinik</name>
      <address>
        <city>Reutlingen</city>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Salzgitter</city>
        <zip>38226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Kliniken Landkreis Sigmaringen GmbH</name>
      <address>
        <city>Sigmaringen</city>
        <zip>72488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissen-Stiftungs-Krankenhaus Speyer, Brustzentrum, Gynäkologische Abteilung</name>
      <address>
        <city>Speyer</city>
        <zip>67346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter Frauenklinik Stendal</name>
      <address>
        <city>Stendal</city>
        <zip>39576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Zentralklinikum Suhl gGmbH, Klinik für Frauenheilkunde/Geburtsmedizin</name>
      <address>
        <city>Suhl</city>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Frauenklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harzklinikum Dorothea Christiane Erxleben GmbH, Abteilung Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Wernigerode</city>
        <zip>38855</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Klinik für Gynäkologie und gyn. Onkologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum-Winnenden, Brustzentrum</name>
      <address>
        <city>Winnenden</city>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Witten</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Universitätsklinikum Wuppertal, Landesfrauenklinik</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Robert Bosch Gesellschaft für Medizinische Forschung mbH</investigator_affiliation>
    <investigator_full_name>Matthias Schwab</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>tamoxifen</keyword>
  <keyword>endoxifen</keyword>
  <keyword>endocrine receptor positive breast cancer</keyword>
  <keyword>adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

